Exelixis
EXEL
#1730
Rank
โ‚น1.050 T
Marketcap
โ‚น3,903
Share price
2.43%
Change (1 day)
36.15%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น213.03. In 2023 the company made an earnings per share (EPS) of โ‚น58.48 an increase over its 2022 EPS that were of โ‚น51.02.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น58.4814.61%
2022โ‚น51.02-22.97%
2021โ‚น66.24100%
2020โ‚น33.12-65.09%
2019โ‚น94.88-53.91%
2018โ‚น205.87333.96%
2017โ‚น47.44-260.61%
2016-โ‚น29.54-58.75%
2015-โ‚น71.61-42.45%
2014-โ‚น124.425.3%
2013-โ‚น118.15

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
โ‚น321.87 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น331.69 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น679.71 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น265.84 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,166 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น934.42 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น153.96-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-โ‚น328.50-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น75.19-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA